期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

新型Xa因子抑制剂利伐沙班在心血管系统疾病中的临床应用研究 被引量：5

在线阅读 下载PDF
导出
摘要 新型口服抗凝血药（new oral anticoagulants,NOAC）包括Xa因子抑制剂和凝血酶抑制剂,用于血栓栓塞性疾病的预防与治疗,临床上主要包括急性冠脉综合征（acute coronary syndrome,ACS）、接受髋关节或膝关节置换术的患者静脉血栓栓塞症（venous thromboembolism,VTE）、深静脉血栓形成和肺栓塞以及房颤（atrial fibrillation,AF）引起的脑卒中等。
作者 荆珊 仇琪 杜海燕 林阳
机构地区 首都医科大学附属北京安贞医院临床药理中心
出处 《中国医院用药评价与分析》 2016年第1期139-142,共4页 Evaluation and Analysis of Drug-use in Hospitals of China
基金 科技部"重大新药创制"<心血管疾病等新药临床评价研究技术平台建设>(No.2012ZX09303016) 北京市自然科学基金<基于代谢组学的高胆固醇血症冠心病患者血浆氧化应激生物标记物探索性研究>(No.2153040)
关键词 XA因子抑制剂 心血管系统疾病 急性冠脉综合征 血栓栓塞性疾病 深静脉血栓形成 FIBRILLATION 膝关节置换术 肺栓塞 临床应用 静脉血栓栓塞症
分类号 R972 [医药卫生—药品]
  • 相关文献

参考文献28

  • 1Camm AJ,Lip GY,De Caterina R,et al.2012 focused update of the ESC Guidelines for the management of atrial fibrillation.An updateof the 2010 ESC Guidelines for the management of atrial fibrillation Developed with the special contribution of the European Heart Rhythm Association[J].Eur Heart J,2012,33(21):2719-2747.
  • 2Kearon C,Akl EA,Comerota AJ,et al.Antithrombotic Therapy for VTE disease.Antithrombotic Therapy and Prevention of Thrombosis,9th ed.American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J].Chest,2012,141(2 Suppl):e419S-494S.
  • 3Lansberg MG,O'Donnell MJ,Khatri P,et al.Antithrombotic and thrombolytic therapy for ischemic stroke:Antithrombotic Therapy and Prevention of Thrombosis,9th ed.American College of Chest Physicians Evidence-Based Clinical Practice Guidelines[J].Chest,2012,141(2 Suppl):e601S-636S.
  • 4Enksson BI,Borris LC,Dahl OE,et al.Dose-escalation study of rivaroxaban(BAY 59-7939)—an oral,direct Factor Xa inhibitor—for the prevention of venous thromboembolism in patients undergoing total hip replacement[J].Thromb Res,2007,120(5):685-693.
  • 5Goto S,Zhu J,Liu L,et al.Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia:a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation(ARISTOTLE)Trial[J].Am Heart J,2014,168(3):303-309.
  • 6Ogawa S,Shinohara Y,Kanmuri K.Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with nonvalvular atrial fibrillation.The ARISTOTLE-J study[J].Circ J,2011,75(8):1852-1859.
  • 7Giugliano RP,Ruff CT,Braunwald E,et al.Edoxaban versus warfarin in patients with atrial fibrillation[J].N Engl J Med,2013,369(22):2093-2104.
  • 8Steg PG,Mehta SR,Pollack CV Jr,et al.Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes:the TAO randomized clinical trial[J].JAMA,2013,310(11):1145-1155.
  • 9Cohen M,Bhatt DL,Alexander JH,et al.Randomized,doubleblind,dose-ranging study of otamixaban,a novel,parenteral,shortacting direct factor Xa inhibitor,in percutaneous coronary intervention:the SEPIA-PCI trial[J].Circulation,2007,115(20):2642-2651.
  • 10Connolly SJ,Eikelboom J,Dorian P,et al.Betrixaban compared with warfarin in patients with atrial fibrillation:results of a phase 2,randomized,dose-ranging study(Explore-Xa)[J].Eur Heart J,2013,34(20):1498-1505.

同被引文献38

引证文献5

二级引证文献19

中国医院用药评价与分析
2016年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部